US
Uzi Sofer
CEO & Chairman
Chairman
born 1970comp · ₪1,261,000
LOADING SNAPSHOT
Fetching the books…
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
For commercial pharma: watch patent cliffs and competition. For pre-revenue biotech: cash runway and trial readouts.
Mixed signals — interesting but with caveats. Worth a deeper look before committing capital.
| Period | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — |
| 2022-12-31 | — | — | ₪-32.14M | ₪-33.76M | — |
| 2023-12-31 | — | — | ₪-35.68M | ₪-29.16M | — |
| 2024-12-31 | — | — | ₪-36.04M | ₪-31.75M | — |
| 2025-12-31 | — | — | ₪-42.29M | ₪-42.63M | — |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.